Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.77 USD

1.77
1,216,822

+0.20 (12.74%)

Updated May 31, 2024 04:00 PM ET

After-Market: $1.78 +0.01 (0.56%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Accuray (ARAY) Down 13.7% Since Earnings Report: Can It Rebound?

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    New Strong Sell Stocks for May 23rd

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

      New Strong Sell Stocks for May 11th

      Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

        New Strong Sell Stocks for May 9th

        Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

          Accuray (ARAY) Q3 Loss Wider Than Estimates, Revenues Top

          Radixact System and major software overhaul drive Accuray (ARAY) in Q3.

            Accuray Radixact Picked by India's Apollo for Cancer Treatment

            Accuray's (ARAY) flagship Radixact radiotherapy platform to help in cancer treatment at Apollo Hospital Group in New Delhi and Chennai, India.

              Accuray's CyberKnife Treats First Patient at Erasmus MC

              Accuray (ARAY) and Erasmus MC partner to develop CyberKnife platform to simplify diagnosis of oligometastatic diseases.

                Accuray Banks on Acquisition & Partnership Amid Competition

                Accuray's (ARAY) partnerships with Premier and Amerinet are expected to help the company gain significant penetration in hospitals and oncology centers.

                  Varian Medical Receives Regulatory Nod for Sirtex Buyout

                  The acquisition of Sirtex will fortify Varian Medical's (VAR) footprint in Australia. The transaction is likely to close in late May 2018.

                    Sanghamitra Saha headshot

                    Here's Why Small-Cap HealthCare ETFs & Stocks Are Good Picks

                    Two reasons why small-cap healthcare stocks and ETFs could be winners in the coming days.

                      Accuray Gains on Radixact Unit, Solid Geographical Foothold

                      Radixact and TomoTherapy along with solid global prospects are the key catalysts for Accuray (ARAY).

                        Cogentix Medical (CGNT) Looks Good: Stock Adds 13.3% in Session

                        The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.

                          Why Is Accuray (ARAY) Down 8% Since its Last Earnings Report?

                          Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                            AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up

                            Strong Growth in Pharmaceutical Distribution Segment and World Courier business drove AmerisourceBergen (ABC) in Q1.

                              Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid

                              Strong growth in BD Medical and BD Life sciences segments drove Becton, Dickinson's (BD) top line in Q1.

                                athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4

                                Strong growth in Business and Services segment drove athenahealth's (ATHN) top line in Q4.

                                  Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up

                                  Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.

                                    Quest Diagnostics (DGX) Tops Q4 Earnings, 2018 View Strong

                                    Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.

                                      Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top

                                      In Q4, Boston Scientific (BSX) registers balanced growth across all business lines and geographies.

                                        Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4

                                        Conmed (CNMD) benefits from impressive general surgery performance and enhanced innovation in Q4.

                                          McKesson (MCK) Beats on Q3 Earnings & Revenues, Ups '18 View

                                          Strong Performance in Distribution Solutions segment drives McKesson (MCK) in Q3. An impressive FY18 outlook instills investor's optimism.

                                            Baxter (BAX) Beats on Q4 Earnings & Revenues, '18 View Solid

                                            Strong performance in the Hospital Products and Renal Products segments drives Baxter (BAX) in Q4.

                                              IDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues

                                              IDEXX (IDXX) rides high on strength in CAG business in Q4. A raised guidance buoys optimism.

                                                4 Reasons Why You Should Buy Accuray (ARAY) Stock Right Now

                                                Accuray (ARAY) rides high on its Radixact platform and latest software overhaul.

                                                  Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands

                                                  Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands